Theravance Shareholders Approve $17/Share Zymeworks Merger; Closing Expected Sept 23
TBPH sits 30% above its 52-week low of $13.08.
Summary
Theravance Biopharma shareholders approved the Zymeworks acquisition at $17.00 per share in cash plus a CVR, with closing expected on or about September 23, 2026.
Key Events · M&A and Partnerships · TBPH
-
Merger Proposal Approved
Shareholders approved the Zymeworks merger with 40,993,370 votes for, 8,671 against, and 84,733 abstentions, representing 79.14% of outstanding shares.
-
Compensation Proposal Approved
The advisory vote on merger-related executive compensation passed with 40,587,829 votes for, 470,381 against, and 28,564 abstentions.
-
Closing Expected September 23
Subject to remaining conditions, the merger is expected to be completed on or about September 23, 2026, at $17.00 per share in cash plus a contingent value right.
-
Key Closing Condition Met
Approval by more than two-thirds of ordinary shares satisfies one of the closing conditions under the merger agreement.
Analysis · TBPH · Life Sciences
Theravance Biopharma shareholders overwhelmingly approved the acquisition by Zymeworks at $17.00 per share in cash plus a contingent value right, with 40,993,370 votes in favor versus only 8,671 against. The vote satisfies a key closing condition under the merger agreement, and the company now expects the deal to close on or about September 23, 2026. With 79.14% of outstanding shares represented at the meeting, the approval removes the last major shareholder-level hurdle to completing the transaction.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 36.7% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TBPH was trading at $17.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $883.7M. The 52-week trading range was $13.08 to $21.03. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.